Evaluation of TAX ,HBZand BCL-XL Gene Expression in Adult T cell Leukemia/Lymphoma (ATL) and HealthyCarriers.

Publish Year: 1394
نوع سند: مقاله کنفرانسی
زبان: English
View: 780

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

NASTARANCANSER01_049

تاریخ نمایه سازی: 26 شهریور 1395

Abstract:

HTLV-I is a worldwide distribution retrovirus with 10-20 million infected individuals. Northeast of Iran especially Mashhad is one of the endemic areas. In spite of the healthy carriersare the majority of HTLV-I-infected individuals but small proportion of infected populationdeveloped two progressive diseases: ATL and HAM/TSP. ATLL is an Adult T Cell leukaemialymphoma caused by the aggressive T-cell proliferation that infected by HTLV-1 and isassociated with a very poor prognosis. BCL-XL belongs to BCL2 family which inhibitsapoptosis in cell so over express of this gene may promote the uncontrolled cell proliferation.TAX and HBZ are two major oncoprotein which they are the main cause of malignancy whichmay interrupt in apoptosis, therefore in this study co expression of TAX, HBZ and BLC-XLwere evaluated. In this study, 37 HTLV-I infected individuals including 17 asymptomatic 20ATL subjects were investigated. mRNA were extracted and convert to CDNA from Peripheralblood mononuclear cells (PBMCs) then expression of TAX,HBZ and BCL-XL investigated byTaqMan qPCR. The analysis of data showed a significant difference in mean of TAX andHBZ expression among study groups (ATL and carriers P= (0.003) and P= (0.000)respectively, Inspite of BCL-Xl elevated gene expression it seems no difference betweenstudies groups (P=0.323).The present study demonstrated that TAX and HBZ were higher inATL group in comparison with healthy carriers. With the regard to BCl-XL gene expressionresults it’s suggested this anti apoptotic pathway might not be involved in malignancy;Therefore, TAX and HBZ can be used as prognostic and monitoring marker for the efficiencyof therapeutic regime and prognosis of HTLV-I associated malignancy.

Keywords:

Authors

Abass Shirdel

Inflammation and Inflammatory Research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran#Internal Medicine Department, Ghaem Hospital, Mashhad University of Medical Science, Mashhad, Iran

Houshang Rafatpanah

Inflammation and Inflammatory Research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran

Sysed Abdollrahim Razaee

Inflammation and Inflammatory Research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran

Safoura Tarokhian

Inflammation and Inflammatory Research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran

Samane Ramezani

Inflammation and Inflammatory Research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran

Mohammad Mehdi Akbarin

Inflammation and Inflammatory Research Centre, Medical School, Mashhad University of Medical Science, Mashhad, Iran